Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer
NCT03042000Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2017
- Primary completion
- Dec 2020
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
Randomised, open-label trial of capecitabine and oxaliplatin in rectal cancer, sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03042000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042000.